Drugmaker seeks judicial review in CMA excessive-pricing case
Credit: istock/tab1962
The UK antitrust enforcer’s “manifestly” and “irrationally” wrong decision to refuse an extension for a defendant to respond to a supplementary statement of objections should be reviewed by a court, a pharmaceutical company has argued.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now